Novo Nordisk | NVO - Ebit


Novo Nordisk reported DKK5.18B in EBIT for its fiscal quarter ending in June of 2025.





Ebit Change Date
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Aurora Cannabis CAD -35.79M 8.96M Dec/2025
Bausch Health Companies USD 489M 230M Mar/2026
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Canopy Growth CAD -12.66M 1.64M Dec/2025
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Drreddys Laboratories INR 16.37B 3.5B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.18B 118M Mar/2026
Novo Nordisk DKK 59.62B 27.24B Mar/2026
Novo Nordisk DKK 5.18B 37.04B Jun/2025
Pacira USD 4.62M 1.43M Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 75.49M 7M Mar/2026
Sanofi EUR 1.94B 239M Mar/2026
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Zoetis USD 842M 7M Mar/2026